BridgeBio Pharma (BBIO) EBIAT (2019 - 2025)
BridgeBio Pharma's EBIAT history spans 7 years, with the latest figure at -$194.6 million for Q4 2025.
- For Q4 2025, EBIAT rose 27.21% year-over-year to -$194.6 million; the TTM value through Dec 2025 reached -$732.9 million, down 34.89%, while the annual FY2025 figure was -$732.9 million, 34.89% down from the prior year.
- EBIAT for Q4 2025 was -$194.6 million at BridgeBio Pharma, down from -$184.9 million in the prior quarter.
- Across five years, EBIAT topped out at -$2.6 million in Q2 2022 and bottomed at -$267.4 million in Q4 2024.
- The 5-year median for EBIAT is -$162.6 million (2021), against an average of -$150.0 million.
- The largest annual shift saw EBIAT soared 97.49% in 2022 before it crashed 6179.91% in 2023.
- A 5-year view of EBIAT shows it stood at -$152.3 million in 2021, then increased by 7.69% to -$140.6 million in 2022, then decreased by 21.17% to -$170.3 million in 2023, then crashed by 56.98% to -$267.4 million in 2024, then grew by 27.21% to -$194.6 million in 2025.
- Per Business Quant, the three most recent readings for BBIO's EBIAT are -$194.6 million (Q4 2025), -$184.9 million (Q3 2025), and -$183.8 million (Q2 2025).